ea0073pep3.2 | Presented ePosters 3: Pituitary and Neuroendocrinology | ECE2021
Freda Pamela U.
, Fleseriu Maria
, Dreval Alexander V.
, Pokramovich Yulia
, Bondar Irina
, Isaeva Elena
, Huang Wenyu
, Molitch Mark E.
, Macut Djuro P.
, Leonova Nina
, Raverot Gerald
, Yossi Gilgun-Sherki
, Ludlam William H.
, Patou Gary
, Haviv Asi
, Gordon Murray B.
, Biermasz Nienke
, Melmed Shlomo K.
, Strasburger Christian J.
BackgroundInjectable somatostatin receptor ligands (iSRLs) have been a mainstay in acromegaly treatment. Oral octreotide capsules (OOC; MYCAPSSA®) were recently approved in the USA. Results from the placebo-controlled CHIASMA OPTIMAL and open-label CH-ACM-01 studies showed an OOC safety profile consistent with that of iSRLs with no new or unexpected safety signals. Results of the MPOWERED trial have enabled a comparison of OOC safety and ...